Xilio Therapeutics, Inc. (XLO) › Shareholders' EquityXilio Therapeutics, Inc. (XLO) — Shareholders' EquityAnnual figures by fiscal year, from SEC filings.2019: -$29.52M2020: -$83.29M2021: $185.43M2022: $105.65M2023: $36.83M2024: $17.60M2025: $35.27M$35.27M2019Shareholders' Equity (USD)2025Fiscal YearShareholders' EquityChange YoY2025$35.27M+100.4%2024$17.60M-52.2%2023$36.83M-65.1%2022$105.65M-43.0%2021$185.43M+322.6%2020-$83.29M-182.1%2019-$29.52M—Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share